Oneness Biotech saw the highest growth of 0.99% in patent filings in June and no patents were granted in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.49% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Oneness Biotech‘s patent filings and grants. Buy the databook here.
Oneness Biotech has been focused on protecting inventions in European Patent Office(EPO) with one publication in Q2 2024
The European Patent Office(EPO) Patent Office dominates the patent filings with nearly 50% of filings. The European Patent Office(EPO), and United States(US) patent Office are among the top ten patent offices where Oneness Biotech is filings its patents..
AbbVie and Roche could be the strongest competitors for Oneness Biotech
Atopic dermatitis (atopic eczema) related patents lead Oneness Biotech portfolio followed by allergic rhinitis, and allergic asthma
Oneness Biotech has highest number of patents in atopic dermatitis (atopic eczema) followed by allergic rhinitis, allergic asthma.
For comprehensive analysis of Oneness Biotech's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.